Bioequivalence of Two Different Oral Solutions Tipranavir Administered in Combination With Ritonavir to Healthy Volunteers
Completed
Boehringer Ingelheim
Phase 1
2008-04-01
To establish the bioequivalence of the new tipranavir oral solution formulation with the
current tipranavir oral solution formulation following single-dose administration. In each
case, 500 mg tipranavir was coadministered with 200 mg ritonavir.
Dose Ranging Trial of Tipranavir/Ritonavir in Treatment-Experienced HIV Infected Individuals
Completed
Boehringer Ingelheim
Phase 2
2002-04-01
The purpose of this research study is to determine which of three different dose combinations
of tipranavir and ritonavir, when taken with a standard approved anti-HIV drug therapy, is
most effective and safe. Tipranavir is an investigational protease inhibitor which has been
demonstrated to have in vitro activity against HIV-1.
Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children
Completed
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Phase 2/Phase 3
2002-08-01
Little is known about what treatment combinations are best for HIV infected children. This
study examined the long-term effectiveness of different anti-HIV drug combinations in
children and strategies for switching treatment if the first treatment does not work. The
study enrolled children who had not previously taken anti-HIV medication. Participants in
this study were recruited in the United States, South America and Europe.
Some European children may also enroll in a substudy that will observe changes in body fat in
children taking anti-HIV medications.
Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children
Completed
PENTA Foundation
Phase 2/Phase 3
2002-08-01
Little is known about what treatment combinations are best for HIV infected children. This
study examined the long-term effectiveness of different anti-HIV drug combinations in
children and strategies for switching treatment if the first treatment does not work. The
study enrolled children who had not previously taken anti-HIV medication. Participants in
this study were recruited in the United States, South America and Europe.
Some European children may also enroll in a substudy that will observe changes in body fat in
children taking anti-HIV medications.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
